Seminars in Hematology
Volume 44, Issue 2 , Pages 106-113 , April 2007

Inherited Thrombophilia in Arterial Disease: A Selective Review

References 

  1. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517–1532
  2. Sykes TC, Fegan C, Mosquera D. Thrombophilia, polymorphisms, and vascular disease. Mol Pathol. 2000;53:300–306
  3. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost. 2001;85:584–595
  4. Kottke-Marchant K. Genetic polymorphisms associated with venous and arterial thrombosis: An overview. Arch Pathol Lab Med. 2002;126:295–304
  5. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med. 2002;126:1281–1295
  6. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol. 2005;25:2043–2053
  7. Hankey GJ, Eikelboom JW. Editorial comment—Routine thrombophilia testing in stroke patients is unjustified. Stroke. 2003;34:1826–1827
  8. Reitsma PH. Is hypercoagulability an issue in arterial thrombosis? (No). J Thromb Haemost. 2004;2:692–694
  9. Grant PJ. Is hypercoagulability an issue in arterial thrombosis? (Yes). J Thromb Haemost. 2004;2:690–691
  10. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002;100:3–10
  11. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J. 2003;146:948–957
  12. Ye Z, Liu EHC, Higgins JPT, Keavney BD, Lowe GDO, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: Meta-analysis of 66,155 cases and 91,307 controls. Lancet. 2006;367:651–658
  13. Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie YG. Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: Evidence of a gene-gene interaction. Blood. 2003;101:3037–3041
  14. Middendorf K, Gohring P, Huehns TY, Seidel D, Steinbeck G, Nikol S. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction. Am Heart J. 2004;147:897–904
  15. Burzotta F, Leone AM, Paciaroni K, De Stefano V, Rossi E, Testa L, et al. G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. Haematologica. 2004;89:1134–1138
  16. Rallidis LS, Belesi CI, Manioudaki HS, Chatziioakimidis VK, Fakitsa VC, Sinos LE, et al. Myocardial infarction under the age of 36: Prevalence of thrombophilic disorders. Thromb Haemost. 2003;90:272–278
  17. Segev A, Ellis MH, Segev F, Friedman Z, Reshef T, Sparkes JD, et al. High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardiol. 2005;98:421–424
  18. Brouwer JL, Veeger NJ, van der Schaaf W, Kluin-Nelemans HC, van der Meer J. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III (Results from a family cohort study to assess the clinical impact of a laboratory test-based classification). Br J Haematol. 2005;128:703–710
  19. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: Thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol. 2004;61:1652–1661
  20. Aznar J, Mira Y, Vaya A, Corella D, Ferrando F, Villa P, et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost. 2004;91:1031–1034
  21. Rubattu S, Di Angelantonio E, Nitsch D, Gigante B, Zanda B, Stanzione R, et al. Polymorphisms in prothrombotic genes and their impact on ischemic stroke in a Sardinian population. Thromb Haemost. 2005;93:1095–1100
  22. Finazzi G, Barbui T. Different incidence of venous thrombosis in patients with inherited deficiencies of antithrombin III, protein C and protein S. Thromb Haemost. 1994;71:15–18
  23. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, et al. The Atherosclerosis Risk in Communities (ARIC) Study Investigators Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation. 1999;100:736–742
  24. Knuiman MW, Folsom AR, Chambless LE, Liao D, Wu KK. Association of hemostatic variables with MRI-detected cerebral abnormalities: The Atherosclerosis Risk in Communities Study. Neuroepidemiology. 2001;20:96–104
  25. Hankey GJ, Eikelboom JW, van Bockxmeer FM, Lofthouse E, Staples N, Baker RI. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke. 2001;32:1793–1799
  26. Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Studies on congenital protein C deficiency in Japanese: prevalence, genetic analysis, and relevance to the onset of arterial occlusive diseases. Semin Thromb Hemost. 2000;26:11–16
  27. Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. Blood. 1998;92:2353–2358
  28. Haywood S, Liesner R, Pindora S, Ganesan V. Thrombophilia and first arterial ischaemic stroke: A systematic review. Arch Dis Child. 2005;90:402–405
  29. Strater R, Becker S, von Eckardstein A, Heinecke A, Gutsche S, Junker R, et al. Prospective assessment of risk factors for recurrent stroke during childhood—A 5-year follow-up study. Lancet. 2002;360:1540–1545
  30. Gunther G, Junker R, Strater R, Schobess R, Kurnik K, Heller C, et al. Childhood Stroke Study Group Symptomatic ischemic stroke in full-term neonates: Role of acquired and genetic prothrombotic risk factors. Stroke. 2000;31:2437–2441
  31. Mercuri E, Cowan F, Gupte G, Manning R, Laffan M, Rutherford M, et al. Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics. 2001;107:1400–1404
  32. Karttunen V, Hiltunen L, Rasi V, Vahtera E, Hillbom M. Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis. 2003;14:261–268
  33. Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. Stroke. 2003;34:28–33
  34. Sastry S, Riding G, Morris J, Taberner D, Cherry N, Heagerty A, et al. Young Adult Myocardial Infarction and Ischemic Stroke: The role of paradoxical embolism and thrombophilia (The YAMIS Study). J Am Coll Cardiol. 2006;48:686–691
  35. Renner W, Koppel H, Brodmann M, Pabst E, Schallmoser K, Toplak H, et al. Factor II G20210A and factor V G1691A gene mutations and peripheral arterial occlusive disease. Thromb Haemost. 2000;83:20–22
  36. Foley PW, Irvine CD, Standen GR, Morse C, Smith FT, McGrath C, et al. Activated protein C resistance, factor V Leiden and peripheral vascular disease. Cardiovasc Surg. 1997;5:157–160
  37. Sampram ES, Lindblad B, Dahlback B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg. 1998;28:624–629
  38. Reny JL, Alhenc-Gelas M, Fontana P, Bissery A, Julia PL, Fiessinger JN, et al. The factor II G20210A gene polymorphism, but not factor V Arg506Gln, is associated with peripheral arterial disease: Results of a case-control study. J Thromb Haemost. 2004;2:1334–1340
  39. Mueller T, Marschon R, Dieplinger B, Haidinger D, Gegenhuber A, Poelz W, et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: The Linz Peripheral Arterial Disease (LIPAD) study. J Vasc Surg. 2005;41:808–815
  40. Sofi F, Lari B, Rogolino A, Marcucci R, Pratesi G, Dorigo W, et al. Thrombophilic risk factors for symptomatic peripheral arterial disease. J Vasc Surg. 2005;41:255–260
  41. Ray SA, Rowley MR, Loh A, Talbot SA, Bevan DH, Taylor RS, et al. Hypercoagulable states in patients with leg ischaemia. Br J Surg. 1994;81:811–814
  42. Ray SA, Rowley MR, Bevan DH, Taylor RS, Dormandy JA. Hypercoagulable abnormalities and postoperative failure of arterial reconstruction. Eur J Endovasc Surg. 1997;17:363–370
  43. Eldrup-Jorgensen J, Flanigan DP, Brace L, Sawchuk AP, Mulder SG, Anderson CP, et al. Hypercoagulable states and lower limb ischemia in young adults. J Vasc Surg. 1989;9:334–341
  44. Allaart CF, Aronson DC, Ruys T, Rosendaal FR, van Bockel JH, Bertina RM, et al. Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost. 1990;64:206–210
  45. Eskandari MK, Bontempo FA, Hassett AC, Faruki H, Makaroun MS. Arterial thromboembolic events in patients with the factor V Leiden mutation. Am J Surg. 1998;176:122–125
  46. Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood. 1997;89:1963–1967
  47. Eitzman DT, Westrick RJ, Shen Y, Bodary PF, Gu S, Manning SL, et al. Homozygosity for factor V Leiden leads to enhanced thrombosis and atherosclerosis in mice. Circulation. 2005;111:1822–1825
  48. Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol. 1995;26:54–661
  49. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, et al. Factor V Leiden increases the risk of myocardial infarction in young women. Blood. 1997;89:2817–2821
  50. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood. 1997;90:1747–1750
  51. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost. 2005;3:1213–1217
  52. Martinelli I, Battaglioli T, Burgo I, Di Domenico S, Mannucci PM. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica. 2006;91:844–847
  53. Vig S, Chitolie A, Sleight S, Bevan D, Dormandy J, Thompson MM, et al. Prevalence and risk of thrombophilia defects in vascular patients. Eur J Vasc Endovasc Surg. 2004;28:124–131
  54. Aleksic M, Jahn P, Heckenkamp J, Wielckens K, Brunkwall J. Comparison of the prevalence of APC-resistance in vascular patients and in a normal population cohort in Western Germany. Eur J Vasc Endovasc Surg. 2005;30:160–163
  55. Vig S, Chitolie A, Bevan D, Dormandy J, Thompson MM, Halliday A. The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease. Br J Surg. 2006;93:577–581
  56. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348:1435–1441
  57. Becattini C, Agnelli G, Prandoni P, Silingardi M, Salvi R, Taliani MR, et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J. 2005;26:77–83
  58. Bova C, Marchiori A, Noto A, Rossi V, Daniele F, Santoro C, et al. Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism (A retrospective cohort study). Thromb Haemost. 2006;96:132–136
  59. Prandoni P, Ghirarduzzi A, Prins MH, Pengo V, Davidson BL, Sorensen H, et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost. 2006;4:1891–1896
  60. Eliasson A, Bergqvist D, Bjorck M, Acosta S, Sternby NH, Ogren M. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: A population study based on 23,796 consecutive autopsies. J Thromb Haemost. 2006;4:1897–1902
  61. van der Hagen PB, Folsom AR, Jenny NS, Heckbert SR, O’Meara ES, Reich LM, et al. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost. 2006;4:1903–1908
  62. Reich LM, Folsom AR, Key NS, Boland LL, Heckbert SR, Rosamond WD, et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost. 2006;4:1909–1913
  63. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642–645
  64. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005;118:978–980
  65. Petrauskiene V, Falk M, Waernbaum I, Norberg M, Eriksson JW. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia. 2005;8:1017–1021
  66. Deguchi H, Pecheniuk NM, Elias DJ, Averell PM, Griffin JH. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation. 2005;112:893–899
  67. Vossen CY, Rosendaal FR EPCOT Study Group. Risk of arterial thrombosis in carriers of familial thrombophilia. J Thromb Haemost. 2006;4:916–918
  68. Gerdes VE, ten Cate H, de Groot E, Kwa VI, Prins MH, Reitsma PH, et al. Amsterdam Vascular Medicine Group Arterial wall thickness and the risk of recurrent ischemic events in carriers of the prothrombin G20210A mutation with clinical manifestations of atherosclerosis. Atherosclerosis. 2002;163:135–140
  69. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol. 1997;17:1325–1330
  70. Atherosclerosis, Thrombosis, and Vascular Biology Italian Group. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation. 2003;107:1117–1122
  71. Coppens M, van der Poel MH, Bank I, Hamulyak K, van der Meer J, Veeger NJ, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood. 2006;108:2604–2607
  72. Nydegger U, Wuillemin WA, Julmy F, Meyer BJ, Carrel TP. Association of ABO histo-blood group B allele with myocardial infarction. Eur J Immunogenetics. 2003;30:201–206
  73. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl):401S–428S

PII: S0037-1963(07)00009-1

doi: 10.1053/j.seminhematol.2007.01.008

Seminars in Hematology
Volume 44, Issue 2 , Pages 106-113 , April 2007

Article Tools